Three deals for Qiagen
Qiagen (NMarkt:QIA; QGENF) subsidiary Qiagen Genomics and Agilent (A) agreed to promote each others' technologies in combination for SNP genotyping and to work together to develop applications of their respective technologies for drug discovery and pharmacogenetic research. Also the companies will jointly develop QIA's Masscode tag chemistry and mass spectrometry instrumentation solutions for SNP discovery, proteomics and other applications.
In a second, non-exclusive deal, the University of Washington's School of Pharmacy will use Qiagen Genomics' Masscode technology for high throughput SNP genotyping of cytochrome P450 enzymes. Qiagen Genomics has exclusive rights to negotiate with the university for any new invention resulting from the university's use of Masscode in its P450 program. ...